Xenon Seven

Xenon Seven

Senior Manager/Associate Director, Marketing Operations & Commercial Review

Boston · Director

Sponsorship not specifiedDetected 21 hours ago
RESTContent MarketingClinical TrialsLeadershipOrganizational Skills

About the role

  • This role will work in close partnership with Marketing, Regulatory, Legal, Medical Affairs, Compliance, and IT to ensure seamless coordination, efficient processes, and strong governance across all marketing activities.
  • This position is critical in a fast-paced, pre-launch environment and requires a highly organized, proactive leader with deep experience in marketing operations, MLR/CRC processes, and cross-functional execution.
  • This position reports to the Vice President, Commercial Operations, and will be based out of Boston, MA, USA in our Needham office.

Responsibilities

  • proactively propose and implement solutions to enhance efficiency and quality
  • Serve as primary CRC operations lead, either directly coordinating reviews or managing an outsourced/vendor-supported model depending on capacity and business needs
  • Establish and manage CRC governance forums, including coordinating CRC steering committees, setting agendas, and aligning stakeholders on process improvements and priorities
  • Lead and coordinate the Executive Review Committee escalation governance committee
  • Partner with IT and cross-functional teams to manage systems supporting CRC workflows (e.g., Veeva PromoMats or similar), including user access, license management, and system enhancements
  • Lead the development and delivery of training programs for CRC processes, systems, and ways of working across Marketing and cross-functional partners
  • identify opportunities and drive adoption of new capabilities to improve efficiency and scalability
  • Continuously assess and improve CRC workflows, identifying bottlenecks, redundancies, and cycle-time challenges; proactively propose and implement solutions to enhance efficiency and quality
  • Stay current on industry best practices, emerging technologies, and innovation (including AI-enabled content and review solutions); identify opportunities and drive adoption of new capabilities to improve efficiency and scalability
  • Develop and align stakeholders to a forward-looking roadmap for content operations maturity and implement prioritized enhancements

Requirements

  • Bachelor's degree required
  • 6-10+ years of experience in marketing operations within pharmaceutical/biotech or agency environments
  • Demonstrated experience with:
  • Strong understanding of regulatory and compliance requirements in pharmaceutical marketing
  • Experience in launch or pre-launch environments, particularly in specialty or rare disease
  • Experience with Veeva PromoMats or similar systems
  • Experience implementing process improvements or transformation initiatives

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Benefits

  • Lead the design, optimization, and execution of the Commercial Review Committee (CRC/MLR) process, ensuring alignment with Marketing, Regulatory, Legal, Medical, and Compliance stakeholders
  • Act as a central point of coordination across Marketing, Regulatory, Legal, Medical, and Compliance to ensure alignment on priorities and timelines

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.